Rho kinase inhibitors: a patent review (2014 – 2016)

<div> <div> <div> <p>Conjugation techniques are central to improving intracellular delivery of bioactive small molecules. However, tracking and assessing the overall biological outcome of these constructs remains poorly understood. We addressed this issue by having developed a focused library of heterobivalent constructs based on Rho kinase inhibitors to probe various scenarios. By comparing induction of a phenotype of interest vs. cell viability vs. cellular uptake, we demonstrate that such conjugates indeed lead to divergent cellular outcomes. </p> </div> </div> </div>

Download Full-text

Faculty Opinions recommendation of Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725421408.793516995 ◽

2016 ◽

Author(s):

Victoria Sanz-Moreno

Keyword(s):

Cell Migration ◽

Melanoma Cell ◽

Kinase Inhibitors ◽

Rho Kinase ◽

Rho Kinase Inhibitors

Download Full-text

Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications

Current Pharmaceutical Design ◽

10.2174/138161212800672688 ◽

2012 ◽

Vol 18 (20) ◽

pp. 2964-2973 ◽

Cited By ~ 16

Author(s):

Hong Zhou ◽

Yong-jun Li

Keyword(s):

Diabetic Complications ◽

Kinase Inhibitors ◽

Rho Kinase ◽

Rho Kinase Inhibitors

Download Full-text

Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

International Journal of Molecular Sciences ◽

10.3390/ijms22031170 ◽

2021 ◽

Vol 22 (3) ◽

pp. 1170

Author(s):

Arunbalaji Pugazhendhi ◽

Margaret Hubbell ◽

Pooja Jairam ◽

Balamurali Ambati

Keyword(s):

Risk Factors ◽

Macular Degeneration ◽

Kinase Inhibitors ◽

Rho Kinase ◽

The Elderly ◽

Age Related Macular Degeneration ◽

Gene Therapies ◽

Rho Kinase Inhibitors ◽

Age Related ◽

Endothelial Growth Factor

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

Download Full-text